INGREZZA Product Sales: $545 million in first quarter product sales. CRENESSITY Net Revenue: $15 million in the first full quarter of launch. 2025 Sales Guidance for INGREZZA: Reaffirmed at $2.5 billion to $2.6 billion. R&D Expense: $45 million in milestone expense for the initiation of osavampator Phase III program in MDD. Cash Balance: Approximately $1.8 billion. Shares Retired: 3.6 million shares over the past two quarters. CRENESSITY Enrollment Forms: 413 enrollment forms with 70% of dispenses receiving reimbursement. Warning! GuruFocus has detected 3 Warning Signs with NBIX. Release Date: May 05, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Neurocrine Biosciences Inc (NASDAQ:NBIX) reported record new patient starts for INGREZZA in the first quarter, indicating strong market demand. The company successfully launched CRENESSITY, achieving $15 million in net revenue with 70% of dispensers receiving reimbursement. Neurocrine Biosciences Inc (NASDAQ:NBIX) expanded formulary coverage for INGREZZA in Medicare Part D, significantly increasing patient access. The company initiated multiple Phase III studies for its pipeline, including osavampator and NBI-'568, demonstrating progress in R&D. Neurocrine Biosciences Inc (NASDAQ:NBIX) maintains a strong financial position with approximately $1.8 billion in cash, supporting future growth and investment. Negative Points First quarter sales for INGREZZA were impacted by one less order week and patient reauthorization processes, affecting revenue. The reauthorization process for continuing patients was more challenging than in previous years, impacting patient retention. Gross-to-net dynamics and contracting activities are expected to impact INGREZZA's financial performance in the short term. The launch of CRENESSITY is still in its early stages, and long-term adoption and reimbursement trends remain uncertain. The Inflation Reduction Act has influenced payer behavior, creating challenges in the reimbursement dynamics for specialty medicines like INGREZZA. Q & A Highlights Q: Can you comment on the challenges faced by INGREZZA in Q1 and the outlook for Q2? A: Kyle Gano, Chief Business Development and Strategy Officer, explained that Q1 faced challenges such as low momentum, reauthorization difficulties, and gross-to-net impacts. However, record new patient starts in Q1 provide confidence for Q2 and beyond. The company expects growth recovery in Q2 and acceleration in the second half of the year due to sales force expansion and improved access. Story Continues Q: How should we view the initial 400 treatment forms for CRENESSITY? Is this a bolus or just the beginning? A: Eric Benevich, Chief Commercial Officer, stated that while it's too early to define a trend, the initial adoption exceeded expectations. The company will continue to monitor the pattern of treatment forms and provide updates in future quarters. Q: Can you provide insights into CRENESSITY's payer dynamics and reimbursement rates? A: Eric Benevich noted that 70% of CRENESSITY fills in the quarter were reimbursed, exceeding expectations. However, most plans have not yet conducted formal formulary reviews, and reimbursement is currently through exceptions processes. The company expects formal reviews to occur throughout the year. Q: What is the current share split between INGREZZA and Teva for new-to-treatment TD patients? A: Eric Benevich mentioned that while exact share splits are not disclosed, INGREZZA continues to hold the majority of prescriptions in the TD market. The company is seeing an equal distribution of pediatric and adult patients for CRENESSITY, with a trend towards more pediatric and adolescent patients. Q: What are the expectations for INGREZZA's growth in Q2 2025 compared to Q1? A: Matthew Abernethy, Chief Financial Officer, indicated that Q2 should see a sequential benefit from an additional order week and record new patient starts. However, a sequential hit in gross-to-net is expected due to contracting activities, which may slightly dampen growth. Q: How are doctors managing glucocorticoid down titration with CRENESSITY, and what is the adoption rate at centers of excellence versus community centers? A: Eric Benevich reported adoption across both centers of excellence and community centers. Eiry Roberts, Chief Medical Officer, added that the label allows flexibility in steroid reduction, and clinicians are engaged in learning how to use CRENESSITY effectively. Q: What are the implications of the recent Cobenfy study failure for Neurocrine's schizophrenia program? A: Eiry Roberts stated that the Cobenfy study highlights the challenges in adjunctive schizophrenia trials but does not affect confidence in Neurocrine's '568 program. The company remains focused on its Phase III program for '568 in acute psychosis. Q: Can you provide details on the Phase III program for osavampator in major depressive disorder? A: Eiry Roberts explained that the program includes three key studies: two short-term randomized placebo-controlled studies and one long-term open-label study. The studies are powered to measure an effect size smaller than seen in Phase II, with a focus on minimizing placebo response. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. View Comments
Neurocrine Biosciences Inc (NBIX) Q1 2025 Earnings Call Highlights: Strong INGREZZA Sales and ...
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...